ondansetron has been researched along with Alcoholism in 37 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron was very well tolerated; hence, further long-term studies with 5-HT3 antagonists alone or in combination with other treatment components may offer promise for treatment of alcoholism." | 6.67 | Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. ( Romach, MK; Sellers, EM; Sobell, LC; Sobell, MB; Somer, GR; Toneatto, T, 1994) |
| " This study tests this hypothesis by matching nontreatment-seeking alcohol-dependent (AD) individuals with LL genotype to ondansetron and SS/SL genotypes to the SSRI sertraline, and mismatching them assessing naturalistic and bar-laboratory alcohol drinking." | 5.19 | Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study. ( Beaucage, K; Brickley, M; Clifford, JS; Fricchione, S; Haass-Koffler, CL; Kenna, GA; Leggio, L; McGeary, JE; Shoaff, JR; Swift, RM; Vuittonet, C; Zywiak, WH, 2014) |
| "Ondansetron has been shown to be an effective treatment for early-onset alcoholism." | 5.10 | Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. ( Ait-Daoud, N; Johnson, BA; Ma, JZ; Wang, Y, 2003) |
| " Medications such as sertraline, ondansetron, topiramate, and aripiprazole represent novel lines of research and are currently being tested for use in the treatment of alcoholism." | 4.82 | Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. ( Kenna, GA; McGeary, JE; Swift, RM, 2004) |
| " late-onset classification is, however, a better predictor of response to ondansetron treatment because it might be more closely related to fundamental neurobiological processes associated with the underlying pathophysiology of alcoholism." | 3.74 | Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism. ( Ait-Daoud, N; Johnson, BA; Roache, JD; Wang, Y, 2008) |
| "Mean ondansetron exit dose was 3." | 3.01 | A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder. ( Bice, C; Holmes, T; Ivleva, E; McArdle, M; McNutt, M; Nakamura, A; Palka, J; Patel, Z; Sherwood Brown, E; Tipton, S, 2021) |
| "Evidence suggests that alcohol dependence may be influenced by a genetic interaction that may be gender-specific with temporal changes making pharmacological treatment with serotonergic drugs complex." | 2.79 | Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings. ( Beaucage, K; Brickley, M; Clifford, JS; Fricchione, S; Haass-Koffler, CL; Kenna, GA; Leggio, L; McGeary, JE; Shoaff, JR; Swift, RM; Zywiak, WH, 2014) |
| "Ondansetron was well tolerated and no serious adverse events were registered." | 2.78 | A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil. ( Baltieri, DA; Corrêa Filho, JM, 2013) |
| "Ondansetron by itself was similar to naltrexone and the combination in the overall analysis but intermediate in a region-specific analysis." | 2.73 | Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. ( Anton, RF; Henderson, S; Li, X; Myrick, H; Randall, PK; Voronin, K, 2008) |
| "Oral ondansetron was safe and well tolerated in our sample." | 2.71 | A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. ( Ait-Daoud, N; Cornelius, JR; Dawes, MA; Johnson, BA; Ma, JZ, 2005) |
| "Ondansetron was very well tolerated; hence, further long-term studies with 5-HT3 antagonists alone or in combination with other treatment components may offer promise for treatment of alcoholism." | 2.67 | Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. ( Romach, MK; Sellers, EM; Sobell, LC; Sobell, MB; Somer, GR; Toneatto, T, 1994) |
| "Alcohol addiction is a heterogeneous psychiatric disorder according to both phenotype and etiology." | 2.53 | NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION. ( Cicin-Šain, L; Kovak-Mufić, A; Marušić, S; Matošić, A; Vidrih, B, 2016) |
| "Acamprosate has demonstrated efficacy for treating alcohol dependence in European trials, but with a small effect size." | 2.44 | Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. ( Johnson, BA, 2008) |
| "Alcohol dependence is the third leading cause of preventable death in the USA." | 1.37 | Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. ( Bond, C; Breslin, FJ; Johnson, BA; Lynch, WJ, 2011) |
| "5% European American; 20 EOAs; 20 LOAs) received an oral solution of ondansetron at a dosage of 4 microg/kg twice daily for 8 weeks, together with weekly relapse-prevention therapy." | 1.32 | Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. ( Feinn, R; Hernandez-Avila, C; Kranzler, HR; Pierucci-Lagha, A, 2003) |
| "Buspirone was without important effects on the high alcohol preferring rats." | 1.29 | Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.11) | 18.2507 |
| 2000's | 17 (45.95) | 29.6817 |
| 2010's | 14 (37.84) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Ross, H | 1 |
| Harries, B | 1 |
| Szelest, I | 1 |
| Engelbrecht, R | 1 |
| Umhau, JC | 1 |
| Greene, MC | 1 |
| Kane, J | 1 |
| Alto, M | 1 |
| Giusto, A | 1 |
| Lovero, K | 1 |
| Stockton, M | 1 |
| McClendon, J | 1 |
| Nicholson, T | 1 |
| Wainberg, ML | 1 |
| Johnson, RM | 1 |
| Tol, WA | 1 |
| Sherwood Brown, E | 1 |
| McArdle, M | 1 |
| Palka, J | 1 |
| Bice, C | 1 |
| Ivleva, E | 1 |
| Nakamura, A | 1 |
| McNutt, M | 1 |
| Patel, Z | 1 |
| Holmes, T | 1 |
| Tipton, S | 1 |
| Han, D | 1 |
| Liu, L | 3 |
| Su, X | 2 |
| Johnson, B | 2 |
| Sun, L | 1 |
| Castrén, S | 1 |
| Mäkelä, N | 1 |
| Alho, H | 1 |
| Johnson, BA | 13 |
| Seneviratne, C | 3 |
| Wang, XQ | 3 |
| Ait-Daoud, N | 9 |
| Li, MD | 2 |
| Kenna, GA | 5 |
| Zywiak, WH | 3 |
| Swift, RM | 4 |
| McGeary, JE | 4 |
| Clifford, JS | 2 |
| Shoaff, JR | 2 |
| Vuittonet, C | 1 |
| Fricchione, S | 2 |
| Brickley, M | 2 |
| Beaucage, K | 2 |
| Haass-Koffler, CL | 2 |
| Leggio, L | 3 |
| Hou, J | 1 |
| Taylor, J | 1 |
| Zhang, H | 1 |
| Kranzler, HR | 2 |
| Kang, J | 1 |
| Thompson, MD | 1 |
| Matošić, A | 1 |
| Marušić, S | 1 |
| Vidrih, B | 1 |
| Kovak-Mufić, A | 1 |
| Cicin-Šain, L | 1 |
| Roache, JD | 5 |
| Wang, Y | 2 |
| McGeary, C | 1 |
| Wang, S | 1 |
| Grenga, A | 1 |
| Javors, MA | 1 |
| Penberthy, JK | 1 |
| DiClemente, CC | 1 |
| Kuehn, BM | 1 |
| Lynch, WJ | 1 |
| Bond, C | 1 |
| Breslin, FJ | 1 |
| Paille, F | 1 |
| Corrêa Filho, JM | 1 |
| Baltieri, DA | 1 |
| Pierucci-Lagha, A | 1 |
| Feinn, R | 1 |
| Hernandez-Avila, C | 1 |
| Ma, JZ | 2 |
| McBride, WJ | 1 |
| Lovinger, DM | 1 |
| Machu, T | 1 |
| Thielen, RJ | 1 |
| Rodd, ZA | 1 |
| Murphy, JM | 1 |
| Dawes, MA | 1 |
| Cornelius, JR | 1 |
| Lê, AD | 1 |
| Funk, D | 1 |
| Harding, S | 1 |
| Juzytsch, W | 1 |
| Fletcher, PJ | 1 |
| Shaham, Y | 1 |
| Heilig, M | 1 |
| Egli, M | 1 |
| Myrick, H | 1 |
| Anton, RF | 1 |
| Li, X | 1 |
| Henderson, S | 1 |
| Randall, PK | 1 |
| Voronin, K | 1 |
| Sellers, EM | 2 |
| Toneatto, T | 1 |
| Romach, MK | 2 |
| Somer, GR | 1 |
| Sobell, LC | 1 |
| Sobell, MB | 1 |
| Meert, TF | 1 |
| Prihoda, TJ | 2 |
| Hargita, ID | 1 |
| Javors, M | 1 |
| Zanca, NA | 2 |
| Gordon, SM | 1 |
| Velazquez, M | 1 |
| Higgins, GA | 1 |
| Tompkins, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacological Treatment for Alcoholism[NCT00382642] | Phase 3 | 283 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Matching Genotypes and Serotonergic Medications for Alcoholism[NCT01113164] | Phase 1 | 79 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study[NCT01187511] | Phase 2 | 44 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics[NCT01227980] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics[NCT00605904] | Phase 2 | 37 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological[NCT03842670] | 140 participants (Anticipated) | Interventional | 2018-11-14 | Active, not recruiting | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.6932 |
| Placebo | 14.6126 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.7646 |
| Placebo | 10.413 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.4075 |
| Placebo | 13.0412 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.9789 |
| Placebo | 15.946 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.9075 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 11.6603 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.9075 |
| Placebo | 13.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.1376 |
| Placebo | 13.1086 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.7805 |
| Placebo | 10.6194 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.7091 |
| Placebo | 13.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.3519 |
| Placebo | 12.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 14.1376 |
| Placebo | 16.9051 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.2805 |
| Placebo | 12.0956 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.2091 |
| Placebo | 10.3813 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.1376 |
| Placebo | 10.0004 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 100 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.977 |
| Placebo | 12.0475 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 15.1645 |
| Placebo | 12.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 20 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 18.4145 |
| Placebo | 15.2497 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 40 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 20.352 |
| Placebo | 18.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 70 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.7895 |
| Placebo | 13.0592 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.8582 |
| Placebo | 8.7076 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.4777 |
| Placebo | 7.041 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.5443 |
| Placebo | 6.6122 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.011 |
| Placebo | 5.4219 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.611 |
| Placebo | 5.7835 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.3112 |
| Placebo | 5.1362 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.2231 |
| Placebo | 4.5648 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2365 |
| Placebo | 4.2791 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6777 |
| Placebo | 5.9457 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6078 |
| Placebo | 6.66 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 10.002 |
| Placebo | 8.7759 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.3187 |
| Placebo | 6.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.6521 |
| Placebo | 8.0633 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.0521 |
| Placebo | 6.5855 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.0521 |
| Placebo | 5.9353 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8092 |
| Placebo | 4.9188 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.149 |
| Placebo | 4.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8071 |
| Placebo | 4.2045 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.2521 |
| Placebo | 7.1569 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6366 |
| Placebo | 6.9188 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.5572 |
| Placebo | 12.2152 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.7 |
| Placebo | 8.8468 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.7 |
| Placebo | 7.3205 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.2715 |
| Placebo | 6.9521 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2715 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.6286 |
| Placebo | 6.6363 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.6083 |
| Placebo | 6.5836 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.7666 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.9858 |
| Placebo | 9.7942 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.1286 |
| Placebo | 8.7942 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.6 |
| Placebo | 12.9 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.7 |
| Placebo | 10.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.5 |
| Placebo | 11.8 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15 |
| Placebo | 12.1 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 18.7 |
| Placebo | 14.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 12.3 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.5 |
| Placebo | 12 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.8 |
| Placebo | 12.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.9 |
| Placebo | 10.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15.3 |
| Placebo | 12.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 17.8 |
| Placebo | 14.4 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.3 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.6 |
| Placebo | 11.2 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.460 |
| Placebo | 5.416 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 1.704 |
| Placebo | 1.766 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.613 |
| Placebo | 3.606 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
8 reviews available for ondansetron and Alcoholism
| Article | Year |
|---|---|
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
Topics: Acamprosate; Alcoholism; Amitriptyline; Developing Countries; Disulfiram; Humans; Male; Mirtazapine; | 2023 |
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
Topics: Acamprosate; Alcoholism; Amitriptyline; Developing Countries; Disulfiram; Humans; Male; Mirtazapine; | 2023 |
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapent | 2019 |
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapent | 2019 |
Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy.
Topics: Alcoholism; Clinical Trials as Topic; Genetic Predisposition to Disease; Genetic Variation; Humans; | 2016 |
Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy.
Topics: Alcoholism; Clinical Trials as Topic; Genetic Predisposition to Disease; Genetic Variation; Humans; | 2016 |
NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain; Disulfiram; Dopamine; gamma-Aminobutyric Acid; G | 2016 |
NEUROBIOLOGICAL BASES OF ALCOHOL ADDICTION.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Brain; Disulfiram; Dopamine; gamma-Aminobutyric Acid; G | 2016 |
Medication treatment of different types of alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; | 2010 |
Medication treatment of different types of alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; | 2010 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2.
Topics: Alcohol Deterrents; Alcoholism; Aripiprazole; Behavior Therapy; Disulfiram; Fructose; Humans; Naltre | 2004 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2.
Topics: Alcohol Deterrents; Alcoholism; Aripiprazole; Behavior Therapy; Disulfiram; Fructose; Humans; Naltre | 2004 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; R | 2008 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; R | 2008 |
17 trials available for ondansetron and Alcoholism
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Bipolar Disorder; Double-Blind Method; Humans; Male; Middle Age | 2021 |
A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Bipolar Disorder; Double-Blind Method; Humans; Male; Middle Age | 2021 |
Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug M | 2013 |
Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug M | 2013 |
Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Female; Genotype; Humans; Male; Middle Aged; Ondansetron; | 2014 |
Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Female; Genotype; Humans; Male; Middle Aged; Ondansetron; | 2014 |
Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.
Topics: Adult; Alcoholism; Double-Blind Method; Female; Genotype; Humans; Male; Middle Aged; Ondansetron; Po | 2014 |
Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.
Topics: Adult; Alcoholism; Double-Blind Method; Female; Genotype; Humans; Male; Middle Aged; Ondansetron; Po | 2014 |
Subgroup Identification in Personalized Treatment of Alcohol Dependence.
Topics: Adult; Aged; Alcoholism; Humans; Middle Aged; Ondansetron; Pharmacogenetics; Precision Medicine; Ser | 2015 |
Subgroup Identification in Personalized Treatment of Alcohol Dependence.
Topics: Adult; Aged; Alcoholism; Humans; Middle Aged; Ondansetron; Pharmacogenetics; Precision Medicine; Ser | 2015 |
A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline.
Topics: Adult; Alcoholism; DNA; Female; Genotype; Humans; Male; Middle Aged; Ondansetron; Patient Acceptance | 2009 |
A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline.
Topics: Adult; Alcoholism; DNA; Female; Genotype; Humans; Male; Middle Aged; Ondansetron; Patient Acceptance | 2009 |
Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Genotype; Humans; M | 2011 |
Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Female; Genotype; Humans; M | 2011 |
A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcoholism; Brazil; Central Nervous System Depressants; Doubl | 2013 |
A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcoholism; Brazil; Central Nervous System Depressants; Doubl | 2013 |
Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
Topics: Adult; Aged; Alcoholism; Confidence Intervals; Double-Blind Method; Female; Humans; Male; Middle Age | 2003 |
Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
Topics: Adult; Aged; Alcoholism; Confidence Intervals; Double-Blind Method; Female; Humans; Male; Middle Age | 2003 |
A prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
Topics: Adolescent; Adult; Alcoholism; Cognitive Behavioral Therapy; Humans; Male; Ondansetron; Patient Comp | 2005 |
A prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
Topics: Adolescent; Adult; Alcoholism; Cognitive Behavioral Therapy; Humans; Male; Ondansetron; Patient Comp | 2005 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manu | 2008 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manu | 2008 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manu | 2008 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manu | 2008 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manu | 2008 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manu | 2008 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manu | 2008 |
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.
Topics: Adult; Alcoholism; Basal Ganglia; Cerebrovascular Circulation; Cues; Diagnostic and Statistical Manu | 2008 |
Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; | 1994 |
Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence.
Topics: Adult; Alcoholism; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; | 1994 |
Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Topics: Adult; Aged; Alcoholism; Analysis of Variance; Double-Blind Method; Drug Therapy, Combination; Femal | 2000 |
Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Topics: Adult; Aged; Alcoholism; Analysis of Variance; Double-Blind Method; Drug Therapy, Combination; Femal | 2000 |
Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Double-Blind Method; Female; Huma | 2001 |
Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Double-Blind Method; Female; Huma | 2001 |
Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Topics: Adult; Alcohol Drinking; Alcoholism; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Fem | 2001 |
Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Topics: Adult; Alcohol Drinking; Alcoholism; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Fem | 2001 |
Ondansetron reduces the craving of biologically predisposed alcoholics.
Topics: Adult; Alcoholism; Analysis of Variance; Behavior, Addictive; Chi-Square Distribution; Double-Blind | 2002 |
Ondansetron reduces the craving of biologically predisposed alcoholics.
Topics: Adult; Alcoholism; Analysis of Variance; Behavior, Addictive; Chi-Square Distribution; Double-Blind | 2002 |
Serotonin and alcohol drinking.
Topics: 1-Naphthylamine; Adult; Alcohol Drinking; Alcoholism; Animals; Double-Blind Method; Fenfluramine; Hu | 1992 |
Serotonin and alcohol drinking.
Topics: 1-Naphthylamine; Adult; Alcohol Drinking; Alcoholism; Animals; Double-Blind Method; Fenfluramine; Hu | 1992 |
12 other studies available for ondansetron and Alcoholism
| Article | Year |
|---|---|
Incorporating ondansetron and baclofen in alcohol use disorder treatment.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Ondansetron | 2023 |
Incorporating ondansetron and baclofen in alcohol use disorder treatment.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Ondansetron | 2023 |
Variable selection for random effects two-part models.
Topics: Adult; Aged; Alcoholism; Computer Simulation; Female; Humans; Longitudinal Studies; Male; Middle Age | 2019 |
Variable selection for random effects two-part models.
Topics: Adult; Aged; Alcoholism; Computer Simulation; Female; Humans; Longitudinal Studies; Male; Middle Age | 2019 |
Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.
Topics: Adult; Age Factors; Age of Onset; Alcohol Drinking; Alcoholism; Antisocial Personality Disorder; Fem | 2008 |
Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.
Topics: Adult; Age Factors; Age of Onset; Alcohol Drinking; Alcoholism; Antisocial Personality Disorder; Fem | 2008 |
Study suggests gene may predict success of therapies for alcohol dependence.
Topics: Alcoholism; Genetic Predisposition to Disease; Humans; Naltrexone; Narcotic Antagonists; Ondansetron | 2011 |
Study suggests gene may predict success of therapies for alcohol dependence.
Topics: Alcoholism; Genetic Predisposition to Disease; Humans; Naltrexone; Narcotic Antagonists; Ondansetron | 2011 |
Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combi | 2011 |
Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combi | 2011 |
[Misuse of alcohol and new drug treatments].
Topics: Alcoholism; Antipsychotic Agents; Aripiprazole; Baclofen; GABA-B Receptor Agonists; Humans; Ondanset | 2011 |
[Misuse of alcohol and new drug treatments].
Topics: Alcoholism; Antipsychotic Agents; Aripiprazole; Baclofen; GABA-B Receptor Agonists; Humans; Ondanset | 2011 |
Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.
Topics: Administration, Oral; Adult; Alcoholism; Ambulatory Care; Chi-Square Distribution; Female; Humans; M | 2003 |
Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.
Topics: Administration, Oral; Adult; Alcoholism; Ambulatory Care; Chi-Square Distribution; Female; Humans; M | 2003 |
Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Ethanol; Humans; Ondansetron; Receptors, Serotonin, 5- | 2004 |
Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism.
Topics: Alcohol Drinking; Alcoholism; Animals; Brain; Ethanol; Humans; Ondansetron; Receptors, Serotonin, 5- | 2004 |
Effects of dexfenfluramine and 5-HT3 receptor antagonists on stress-induced reinstatement of alcohol seeking in rats.
Topics: Alcoholism; Animals; Dexfenfluramine; Electroshock; Indoles; Male; Ondansetron; Rats; Rats, Wistar; | 2006 |
Effects of dexfenfluramine and 5-HT3 receptor antagonists on stress-induced reinstatement of alcohol seeking in rats.
Topics: Alcoholism; Animals; Dexfenfluramine; Electroshock; Indoles; Male; Ondansetron; Rats; Rats, Wistar; | 2006 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati | 1993 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati | 1993 |
Ondansetron for alcoholics.
Topics: Adult; Age of Onset; Alcoholism; Antiemetics; Humans; Ondansetron; Transferrin | 2001 |
Ondansetron for alcoholics.
Topics: Adult; Age of Onset; Alcoholism; Antiemetics; Humans; Ondansetron; Transferrin | 2001 |
Does the alcoholic's remedy come in a pill?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Excitatory Amino Acid Antagonists; Female; | 2001 |
Does the alcoholic's remedy come in a pill?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Excitatory Amino Acid Antagonists; Female; | 2001 |